Lannett Launches Fluvastatin Sodium ER Tablets prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing
News provided by
Share this article
Share this article
PHILADELPHIA, June 1, 2021 /PRNewswire/ Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for Fluticasone Propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg), which was submitted by Lannett on behalf of its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The FDA assigned a Generic Drug User Fee Act of 2017 (GDUFA II) goal date for this priority original ANDA of January 31, 2022.
The product is the generic equivalent of ADVAIR DISKUS
Operator
Welcome to the Lannett Company s Fiscal 2021 Third Quarter Financial Results Conference Call. My name is Hilda and I will be your operator for today. Later, we will conduct a question-and-answer session. [Operator Instructions]
I will now turn the call over to Mr. Robert Jaffe, Investor Relations for Lannett. Mr. Jaffe, you may begin.
Robert Jaffe
Investor Relations for Lannett
Good afternoon, everyone, and thank you for joining us today to discuss Lannett Company s fiscal 2021 third quarter financial results. On the call today are Tim Crew, Chief Executive Officer; John Kozlowski, the company s Chief Financial Officer, Maureen Cavanaugh, our Chief Commercial Operations Officer and Steve Lehrer, who leads our insulin biosimilar initiatives. This call is being broadcast live at www.lannett.com. A playback will be available for at least three months on Lannett s website. I would like to make the cautionary statement and remind everyone that all of the information discu
Share this article
Share this article
PHILADELPHIA, May 5, 2021 /PRNewswire/ Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 third quarter ended March 31, 2021. In recent months, we have significantly advanced a number of strategic initiatives, said Tim Crew, chief executive officer of Lannett. In April, we successfully completed a transaction to refinance our debt, using the proceeds to retire the outstanding Term Loan B balance of approximately $540 million that was set to mature in November of next year. As a result, we have extended the maturity of our debt to 2026 from 2022, which is after several high-value pipeline assets are expected to be commercialized. Moreover, we improved our free cash flow, by approximately $50 million in the first year alone, which we plan to use, in part, to support our growth initiatives.
Lannett Announces Closing Of $350 Million Senior Secured Notes And $190 Million Second Lien Senior Secured Loan Facility prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.